论文部分内容阅读
心房颤动是一种严重威胁人类健康的疾病,心房颤动致残或致死的主要并发症是缺血性卒中.抗凝治疗在心房颤动的卒中预防中起关键作用,近年来多种口服抗凝药物被批准用于心房颤动患者以降低卒中风险.华法林是常用的经典抗凝药物,价格低廉,可降低血栓栓塞发生率,同时也会增加相应的出血风险,华法林个体化基因检测有望平衡血栓和出血风险,使治疗结果达到最优化.现就华法林个体化基因检测的可行性及临床意义做一综述.“,”Atrial fibrillation(AF)is a serious threat to human health.The main complication of AF is ischemic stroke,leading to mortality.Anticoagulant therapy plays a key role in the prevention of stroke in patients with AF.In recent years,a variety of oral anticoagulants have been approved for use in patients with AF to reduce the risk of stroke.Warfarin is a commonly used classic anticoagulant which can reduce the incidence of thromboembolism,but also increases the risk of bleeding.Warfarin individual gene detection is expected to balance the risk of thrombosis and bleeding,and optimize treatment results.The feasibility and clinical significance of individualized detection of warfarin were reviewed in this article.